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320Objective: Gross tumor pulmonary embolism from renal carcinoma is rarely diagnosed preoperatively.
Individual cases of intraoperative embolization of tumor during radical resection of the kidney have been
reported. We report on 9 patients who underwent pulmonary arterial tumor removal concomitant with
nephrectomy.
Methods: Between 2000 and 2008, 9 patients underwent simultaneous nephrectomy and removal of gross em-
bolic tumor from the pulmonary arteries. In 7 of these patients the diagnosis was made preoperatively by either
computed tomography or magnetic resonance imaging. Cardiopulmonary bypass was used in all cases. Bilateral
removal of pulmonary artery tumor was required in 7 patients and unilateral in 2.
Results: All patients survived to hospital discharge after a median stay of 8.8 days (mean, 6–17 days). Two pa-
tients are currently alive 4 and 56 months after the operation. Six patients died of distant metastasis or local re-
currence of disease after 6, 9, 12, 17, 25, and 29 months. Actuarial survival at 6 months, 1, 2, and 3 years was
100%, 75%, 50%, and 25%, respectively.
Conclusions: Pulmonary artery embolic tumor removal concomitant with nephrectomy for renal carcinoma can
be performed safely. Survival of patients with combined surgery is comparable with that of patients with the same
stage of renal neoplasm without pulmonary tumor embolism. The pulmonary tumor embolism in patients with
renal carcinoma should be considered as extension of vena caval tumor but not as a distant metastasis. Pulmonary
tumor removal provides symptomatic relief and may provide a survival benefit in these patients. (J Thorac
Cardiovasc Surg 2010;139:320-5)Concomitant renal neoplasm with pulmonary extension is
uncommon and carries a poor prognosis. The precise inci-
dence of gross pulmonary tumor thromboembolism from
any source of neoplasm is controversial but is estimated to
be between 0.9% and 2.4%.1 Renal cell carcinoma invades
the venous system in approximately 5% to 10% of cases.2,3
Although the possibility of pulmonary embolism is en-
hanced when tumor extends to the inferior vena cava
(IVC) or renal vein,4 gross pulmonary tumor embolism is
rare. Most cases in the literature arise from intraoperative
pulmonary embolization of tumor during resection requiring
emergency pulmonary tumor removal as a lifesaving proce-
dure, and only a limited number of patients have survived.5,6
We report our experience with concomitant pulmonary arte-
rial tumor removal with radical nephrectomy in patients with
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The Journal of Thoracic and Cardiovascular SurgPATIENTS AND METHODS
Between 2000 and 2008, 9 patients with a mean age of 58.3 years (range,
46–69 years) underwent pulmonary tumor removal concomitant with radi-
cal nephrectomy and tumor thrombectomy of the IVC. All patients had renal
vein and IVC involvement and had true tumor embolization into the pulmo-
nary artery. Patients with thrombotic pulmonary embolism with negative
pathology reports for primary renal tumor were excluded inasmuch as the
aim of the study was to assess the effect of pulmonary tumor embolism
and its surgical removal on survival. We analyzed our data related to clinical
presentation, diagnostic methods, operative data, pathologic examination of
specimens, and follow-up. This study has been approved by the Institutional
Review Board of the Mayo Clinic, Rochester, Minnesota.
Clinical Presentation
All but 1 patient with preoperative pulmonary tumor embolism had
shortness of breath related to that. Recent onset of shortness of breath
was the presenting symptom in 4 patients and was present in 2 others.
One patient had long-standing shortness of breath that increased over the
preceding month. Hematuria was the initial symptom in 4 other patients
and flank pain in another. Four patients had recently diagnosed hypertension
and 2 had worsening chronic hypertension. The average time interval
between onset of symptoms and diagnosis was 4.7 weeks (range 1–16
weeks). One patient had a pulmonary metastasis at presentation.
Diagnosis
All patients had computed tomography (CT) to assess the primary tumor
and other sites of potential disease. Six patients underwent magnetic
resonance imaging to better define the presence and extent of intracaval
and pulmonary disease. In 7 patients pulmonary arterial occlusion was
diagnosed preoperatively, and in 2 patients in whom tumor embolus devel-
oped during nephrectomy, the diagnosis was made intraoperatively withery c February 2010
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CPB ¼ cardiopulmonary bypass
CT ¼ computed tomography
IVC ¼ inferior vena cavaFIGURE 1. A, CT of the chest in a patient showing saddle-tumor embolus
in the main pulmonary artery. B, CT of the chest in another patient showing
occlusive thrombus within the right main pulmonary artery and branches
of the left pulmonary artery. (Printed with permission of Mayo Clinic,
Rochester.)transesophageal echocardiography. Although it was not possible to differen-
tiate tumor embolism from thrombotic embolism on the basis of only CT or
magnetic resonance imaging findings, tumor embolism was suspected on
the basis of acute onset of shortness of breath along with the presence of
bulky tumor involving the IVC. Final diagnosis was confirmed by patho-
logic examination of removed specimens. In 7 patients pulmonary tumor
embolus occluded either the main pulmonary artery or its two main branches
(Figure 1). In each of the other patients unilateral pulmonary artery
occlusion was present (Figure 2).
Operation
Intraoperative transesophageal echocardiography was done in all
patients. Laparotomy was performed through a midline or chevron incision
and median sternotomy was then performed. The renal tumor was then
dissected by the standard approaches that we7 previously described. An
important aspect of the operation is early ligation of the renal artery to
help decrease the chance of troublesome venous bleeding. This may also
reduce the cephalad extent of vena caval tumor thrombus because the major
blood supply to the tumor thrombus arises from the renal artery. During
surgical removal of IVC thrombus, it is essential to obtain control of the
cava above the thrombus before manipulating the intracaval tumor mass
to prevent intraoperative embolization of tumor fragments. After comple-
tion of vena caval dissection and proximal and distal control of IVC tumor,
the kidney was mobilized and the small hepatic and lumbar veins were
carefully dissected and ligated. Abdominal tumor was removed before car-
diopulmonary bypass (CPB) in patients with level I and II IVC tumor. In
patients with level III or IV IVC thrombus, the patient was heparinized
and cannulated at this stage for CPB. Deep hypothermic arrest was used
when the blood return from the pulmonary arteries was excessive, prevent-
ing complete removal of tumor embolus. Removal of IVC tumor and
nephrectomy was completed with the patient supported by CPB along
with or after removal of pulmonary tumor thrombus. The abdominal
incision was closed after protamine administration. Meticulous check of
the incision and tumor bed is important to avoid postoperative intra-
abdominal bleeding complications.
Follow-up
A chest radiograph and abdominal, pelvic, and thorax CT were repeated
at 3-month intervals postoperatively. Survival times were calculated from
the date of operation to the date of death or last contact. Survival was calcu-
lated by Kaplan–Meier analysis.
RESULTS
Operative Data
All patients had pulmonary artery tumor embolectomy
while supported by CPB. In 2 patients with intraoperative
embolism, the tumor migrated from the IVC and right
atrium during manipulation of these sites and was diagnosed
by transesophageal echocardiography. Both patients had
stable hemodynamics and arterial oxygen saturations, and
it was possible to proceed with the operation as in elective
patients with a preoperative diagnosis. Pulmonary tumor
embolectomy was performed on CPB with (n ¼ 4) orThe Journal of Thoracic and Cawithout (n ¼ 5) total circulatory arrest. Aortic arterial can-
nulation was performed in all patients and venous cannula-
tion was single atrial or bicaval in 7 patients. In 2 patients
with total caval obstruction, cannulation of the IVC below
the level of the renal veins was performed. In 3 patients,
the aorta was crossclamped to reduce pulmonary bleeding
and facilitate tumor removal. The IVC tumor was removed
during CPB support in patients with level III or IV IVC ex-
tension and before CPB in patients with level I or II IVC ex-
tension. After tumor removal, the IVC was closed primarily
in 8 patients and with a bovine pericardial patch in 1 patient.
In 1 patient with bilateral pulmonary tumor embolism,
wedge resection of a nodule at the right lower lung lobe
was performed, confirming a 2-cm focus of metastatic renal
cell carcinoma. In 2 patients concomitant cholecystectomy
was performed.rdiovascular Surgery c Volume 139, Number 2 321
FIGURE 2. A and B, Intraoperative photographs showing occlusive tumor in the right pulmonary artery. C, Tumor thrombus extirpated from the right
pulmonary artery of the same patient. (Printed with permission of Mayo Clinic, Rochester.)
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DThere was no early mortality. Abdominal re-exploration
for bleeding within 24 hours of the operation was performed
in 1 patient. Transient increase of liver function tests and cre-
atinine was observed in 1 patient each, with return to normal
levels over a few days. Atrial fibrillation was observed in 1
patient and prolonged intubation of 58 hours was required in
another. The average duration of intensive care unit and hos-
pital stays were 2.2 days (1–4 days) and 8.8 days (6–17
days), respectively. Operative and early perioperative data
are listed in Table 1.TABLE 1. Operative and early perioperative data
Variable
Cardiopulmonary bypass
time, average (range)
112.6 min (29–233 min)
Total circulatory arrest
time (4 patients)
20.5 min (13–32 min)
Other procedures
Cholecystectomy 2
Pulmonary resection for metastasis 1
Duration of intubation 20 h (5–58 h)
Duration of intensive care unit stay 2.2 days (1–4 d)
Duration of hospital stay 8.8 days (6–17 d)
Perioperative mortality None
Perioperative morbidity
Abdominal re-exploration for bleeding 1
Transient increase of liver function tests 1
Transient increase of creatinine 1
Atrial fibrillation 1
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Complete surgical removal of the primary tumor was
possible in all patients except one with surgical margin
positivity at the renal vein. The tumor thrombus level in
the IVC was IV in 2 patients and III in 5 patients. The tumor
extension to perinephric fat was present in all patients.
Nuclear grade of renal cell carcinoma was 3 in 7 patients
and 4 in 1 patient. Tumor grade was 3 in the patient with
urothelial carcinoma. Pathologic examination of extracted
material showed gross tumor mass in all patients with coag-
ulative tumor necrosis present in 4. A variable amount of
organized thrombus was present in each extracted embolic
material. Histologic characteristics are summarized in
Table 2.Postoperative Management
A total of 4 patients received immunotherapy or chemo-
therapy after the operation. The patient with the preoperative
pulmonary metastasis received interferon and interleukin 2
treatment consequently. One patient received sorafenib
and 2 patients received sunitinib and interleukin 2 after distal
metastases to the lung and liver developed. Radiotherapy
was administered in 2 patients with spinal involvement.Survival
Follow-up data were obtained for all patients, the follow-
up interval ranging from 4 to 62 months with a mean of 24.4
months. Removal of tumor provided symptomatic relief inery c February 2010
FIGURE 3. Survival curve of patients.
TABLE 2. Pathologic and histologic data
Variables
No. of patients 9
Left/right kidney 3/6
Histologic type
Clear cell type 7
Granular cell type 1
Urothelial cell carcinoma 1
The level of IVC thrombus
Level I 1
Level II 1
Level III 5
Level IV 2
Grade, average (range)
Renal cell carcinoma (of 4) 3.1 (3–4)
Urothelial carcinoma (of 3) 3
Capsular invasion 9
Spread to perinephric fat 9
Lymph node involvement
Positive/negative 3/4
Unknown 2
Preoperative metastasis 1
IVC, Inferior vena cava.
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Dall patients. One-, 2-, 3-, and 5-year survivals after the oper-
ation were 75%, 50%, 25%, and 25%, respectively, with
a median survival of 24.4 months (4–62 months) (Figure 3).
During follow-up, 7 patients with renal cell carcinoma had
distant metastasis or local recurrence of disease. Six patients
died of progressive metastatic disease and 2 patients are
alive 4 and 56 months after the operation (Table 3).
DISCUSSION
Pulmonary embolism in the setting of malignancy is most
frequently associated with a hypercoagulable state and sub-TABLE 3. Follow-up data
Patient Preop. Met. Postop. Met. Postop. therapy St
1 None None None
2 Lung Liver, lung Interferon, IL-2
3 None Bilateral adrenal gland None
4 None Liver, lung, abdomen IL-2
5 None Liver, lung, adrenal gland,
vertebra
Sorafenib, radiotherapy
6 None Lung, liver None
7 None Lung, spine,
retroperitoneal LNs
Radiotherapy
8 None Liver, retroperitoneal LNs Sunitinib, IL-1, sorafenib
9 None None None
Preop, Preoperative; met, metastasis; postop, postoperative; IL-2, interleukin 2; LNs, lymp
The Journal of Thoracic and Casequent thrombotic pulmonary emboli. Usually an autopsy
finding, gross and microscopic pulmonary arterial tumor
embolism occurs in as many as 8% to 20% of advanced can-
cers, the most common primary tumors being lung, breast,
kidney, liver, pancreas, and gastrointestinal tract.8 Pulmo-
nary arterial tumor embolism is rare in patients with renal
carcinoma, and most cases in the literature represent intrao-
perative tumor embolism during mobilization and removal
of primary tumor.5,6,9,10 Preoperative diagnosis of pulmo-
nary tumor embolism in renal cell carcinoma with subse-
quent surgical treatment has been reported in only 3 cases
in the English literature.11-13 Therefore, the optimal treat-
ment strategy in these patients and the impact of concomitant
pulmonary arterial tumor removal on prognosis are
unknown.
The prognosis of patients with renal cell carcinoma with
IVC tumor thrombus extension is unclear. Severalatus (mo of survival) Cause of death
Long-term
complications
Dead (62) Intracranial hemorrhage Recurrent pulmonary
embolism
Dead (9) Progressive disease None
Alive (56) None Percutaneous ablation of
adrenal glands
Dead (29) Progressive disease None
Dead (12) Progressive disease Spine involvement and
pain
Dead (25) Progressive disease None
Dead (6) Progressive disease Spine involvement and
pain
Dead (17) Progressive disease Operation for ileus 2 mo
later, thrombocytopenia
and intraabdominal
bleeding with sunitinib
Alive (4) None None
h nodes.
rdiovascular Surgery c Volume 139, Number 2 323
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Dinvestigators have reported favorable outcomes and sug-
gested that vascular extension per se may not indicate
a more aggressive form of tumor.2,14-16 Overall 5-year sur-
vivals of patients with renal cell carcinoma with tumor
thrombus extension to the IVC were reported to be 25%
to 75% previously.2,15,17-19 Tumor extension beyond the
kidney capsule, regional lymph node and perinephric fat in-
vasion, distant metastatic disease, stage, and histopathologic
grade of tumor are established variables for poor progno-
sis.3,17-20 Total resection of the renal tumor and IVC tumor
thrombus is considered the optimal therapy when no distant
metastases are present.2,14,16 Hatcher and associates2 re-
ported that the prognosis was determined by the ability to
completely resect the tumor, not by the level of tumor throm-
bus. Skinner and colleagues16 emphasized the importance of
complete resection by reporting a 34% 5-year survival for
those patients undergoing a complete resection and a 1-
year survival of only 8% for those who had incomplete resec-
tions. Furthermore, Neves and Zincke21 noted a difference in
5-year survival between patients with complete thrombus re-
moval (68%) and those with incomplete thrombus removal
(17.5%). Five-year survival in the current series is 25%,
which is comparable with that of patients with grade 3 to 4
tumors and perinephric involvement in other series.19-21
The reason for death was progressive metastatic disease in
6 patients. Therefore, it is more likely that survival of these
patients is predicted by metastatic status, grade, and local in-
vasion of the tumor than by pulmonary tumor embolism. This
experience suggests that pulmonary tumor embolism in pa-
tients with renal carcinoma should be considered as exten-
sion of vena caval tumor but not as a distant metastasis.
Therefore, in addition to being a lifesaving procedure for pa-
tients with intraoperative or preoperative massive tumor em-
bolism, pulmonary tumor removal may provide a survival
benefit in these patients, although larger series are required
to better clarify patient selection for these procedures. Care-
ful preoperative evaluation for pulmonary embolus should be
performed in all, but especially in those with recent onset of
shortness of breath or worsening dyspnea over a short period
of time.
Although a staged procedure with either nephrectomy or
pulmonary tumor embolectomy performed first has been
reported,12,13 we preferred concomitant removal of pulmo-
nary tumor embolus and primary renal tumor. We believe
that concomitant operation decreases duration of ventila-
tion and hospital stay compared with a staged ap-
proach.12,13 Although CPB was reported to be associated
with higher overall blood loss, a greater rate of coagulop-
athy, and longer operative times,22 we observed only one
re-exploration for bleeding and only minor morbidity in
this series. Removal of tumor provided symptomatic relief
in all patients. We believe that with careful surgical tech-
nique, use of total circulatory arrest in selected patients,
and meticulous postoperative care, benefits of the pulmo-324 The Journal of Thoracic and Cardiovascular Surgnary tumor removal outweigh the potential morbidity asso-
ciated with CPB. Removing abdominal tumor before CPB
in patients with level I and II tumors and completing the
dissection of abdominal tumor before CPB in patients
with level III and IV caval thrombus are helpful to mini-
mize duration of CPB. The risk of propagating tumor cells
into the systemic circulation can be minimized by using
a discard sucker instead of a cardiotomy sucker when re-
moving the tumor. Use of circulatory arrest during removal
of pulmonary tumor embolus may also decrease the use of
suckers by decreasing the blood return. Although use of the
cell salvage device in oncologic surgery is controversial,
clinical studies with a limited number of patients showed
no metastatic spread after processing of the blood with
such a device. Therefore, it can be used in cases of unex-
pected or excessive bleeding.23
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